{"url_path":"/sec/actu/10-q/2026/body","section_key":"body","section_title":"Body","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1652935/0001683168-26-003909-index.html","accession_number":"0001683168-26-003909","cik":"0001652935","ticker":"ACTU","issuer_name":"ACTUATE THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1652935/0001683168-26-003909-index.html","primary_entity_key":"0001652935","primary_entity_name":"ACTUATE THERAPEUTICS, INC."},"word_count":458,"has_tables":true,"body_markdown":"EX-31.1\n2\nactuate_ex3101.htm\nCERTIFICATION\n\n**Exhibit 31.1**\n\n**Certification**\n\nI, Daniel Schmitt, President and Chief Executive Officer\nof the registrant, certify that:\n\n1. I have reviewed this\nQuarterly Report on Form 10-Q for the quarter ended March 31, 2026 of Actuate Therapeutics, Inc., a Delaware corporation (the “Company”);\n\n2. Based on my knowledge,\nthis report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements\nmade, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;\n\n3. Based on my knowledge,\nthe financial statements, and other financial information included in this report, fairly present in all material respects the financial\ncondition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;\n\n4. The Company’s other\ncertifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act\nRules 13a-15(e) and 15d-15(e)) for the Company and have:\n\na) designed such\ndisclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that\nmaterial information relating to the Company, including its consolidated subsidiaries, is made known to me by others within those entities,\nparticularly during the period in which this report is being prepared;\n\nb) [Paragraph\nomitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313];\n\nc) evaluated\nthe effectiveness of the Company’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness\nof the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and\n\nd) disclosed\nin this report any change in the Company’s internal control over financial reporting that occurred during the Company’s most\nrecent quarter (the Company's fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to\nmaterially affect, the Company’s internal control over financial reporting; and\n\n5. The Company’s other\ncertifying officer and I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the Company’s\nauditors and the audit committee of the Company’s board of directors (or persons performing the equivalent functions):\n\na) all significant\ndeficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely\nto adversely affect the Company's ability to record, process, summarize and report financial information; and\n\nb) any fraud,\nwhether or not material, that involves management or other employees who have a significant role in the Company's internal control over\nfinancial reporting.\n\nDate: May 14, 2026\n\n*/s/ Daniel Schmitt*\n\nDaniel Schmitt\n\nPresident and Chief Executive Officer, Director\n\n(Principal Executive Officer)"}